Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
M Aardoom, Gigi Veereman, Lissy de Ridder
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2529-2529
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics
Quan Lu, Meifeng Yang, Yujie Liang, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 1825-1844
Open Access | Times Cited: 97
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
Guanglin Cui, Qingbo Fan, Zhenfeng Li, et al.
EBioMedicine (2021) Vol. 66, pp. 103329-103329
Open Access | Times Cited: 73
Lactobacillus rhamnosusfrom human breast milk ameliorates ulcerative colitis in miceviagut microbiota modulation
Bing Pang, Jin Han, Ning Liao, et al.
Food & Function (2021) Vol. 12, Iss. 11, pp. 5171-5186
Closed Access | Times Cited: 49
The Role of Gut Microbiota, Immune System, and Autophagy in the Pathogenesis of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutic Approaches
Beatrice Garavaglia, Letizia Vallino, Angela Amoruso, et al.
Aspects of Molecular Medicine (2024), pp. 100056-100056
Open Access | Times Cited: 6
Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center
Roxana Elena Matran, Andra-Mihaela Diaconu, Andreea Maria Iordache, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 84-84
Open Access
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies
Akshita Bhalla, Aakash Shahi, Madhurima Maity, et al.
Cureus (2025)
Open Access
Immunohistochemistry Analysis in Inflammatory Bowel Disease—Should We Bring to Light Interleukin-10?
Christopher Pavel, Mircea Diculescu, Mădălina Ilie, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 406-406
Open Access
Protective Effects of Companilactobacillus crustorum MN047 against Dextran Sulfate Sodium-Induced Ulcerative Colitis: A Fecal Microbiota Transplantation Study
Tao Wang, Caihong Shi, Shuxuan Wang, et al.
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 5, pp. 1547-1561
Closed Access | Times Cited: 25
The Therapeutic Role of Short-Chain Fatty Acids Mediated Very Low-Calorie Ketogenic Diet–Gut Microbiota Relationships in Paediatric Inflammatory Bowel Diseases
Naser A. Alsharairi
Nutrients (2022) Vol. 14, Iss. 19, pp. 4113-4113
Open Access | Times Cited: 22
Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments
M Jongsma, L M M Costes, Irma Tindemans, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1262-1277
Open Access | Times Cited: 11
Protective effect of plantaricin bio-LP1 bacteriocin on multidrug-resistance Escherichia Coli infection by alleviate the inflammation and modulate of gut-microbiota in BALB/c mice model
Mohamedelfatieh Ismael, Nageena Qayyum, Yaxin Gu, et al.
International Journal of Biological Macromolecules (2023) Vol. 246, pp. 125700-125700
Closed Access | Times Cited: 10
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Antonello Di Paolo, Giacomo Luci
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 25
Interaction of Companilactobacillus crustorum MN047-derived bacteriocins with gut microbiota
Tao Wang, Shuxuan Wang, Shuchen Dong, et al.
Food Chemistry (2022) Vol. 396, pp. 133730-133730
Closed Access | Times Cited: 16
Crohn's disease and clinical management today: How it does?
Ronaldo Teixeira da Silva Júnior, Jonathan Santos Apolonio, Jéssica Oliveira de Souza Nascimento, et al.
World Journal of Methodology (2023) Vol. 13, Iss. 5, pp. 399-413
Open Access | Times Cited: 9
Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease
Miikka Höyhtyä, Katri Korpela, Schahzad Saqib, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 1, pp. 116-124
Open Access | Times Cited: 14
Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases
Anne E. Levine, Dominique Mark, Laïla Smith, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 969-969
Open Access | Times Cited: 8
The microbiome landscape in pediatric Crohn’s disease and therapeutic implications
Karin Fetter, Markus Weigel, Benjamin Ott, et al.
Gut Microbes (2023) Vol. 15, Iss. 2
Open Access | Times Cited: 8
Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation
Eun Sil Kim, Hyangah Chon, Yiyoung Kwon, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 4, pp. 460-467
Open Access | Times Cited: 2
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
M Kamal, Rehab H. Werida, Mahasen A. Radwan, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 3259-3269
Open Access | Times Cited: 2
Parkinson’s Disease, It Takes Guts: The Correlation between Intestinal Microbiome and Cytokine Network with Neurodegeneration
Georgia Xiromerisiou, Chrysoula Marogianni, Anastasia Androutsopoulou, et al.
Biology (2023) Vol. 12, Iss. 1, pp. 93-93
Open Access | Times Cited: 7
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Philip J Smith, Mathurin Fuméry, Rupert W. Leong, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1143-1156
Open Access | Times Cited: 7
Aqueous M. oleifera leaf extract alleviates DSS-induced colitis in mice through suppression of inflammation
Shuai Zhang, Yanan Cao, Yanjie Huang, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116929-116929
Closed Access | Times Cited: 7
Body composition in children with chronic inflammatory diseases: A systematic review
Noora Houttu, Marko Kalliomäki, Minna‐Maija Grönlund, et al.
Clinical Nutrition (2020) Vol. 39, Iss. 9, pp. 2647-2662
Closed Access | Times Cited: 18
Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females
Maria Consiglia Trotta, Roberto Alfano, Giovanna Cuomo, et al.
The Journal of Pediatric Pharmacology and Therapeutics (2021) Vol. 27, Iss. 1, pp. 63-71
Open Access | Times Cited: 17
Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis
Bendix Samarta Witarto, Visuddho Visuddho, Andro Pramana Witarto, et al.
Jornal de Pediatria (2023) Vol. 99, Iss. 5, pp. 432-442
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top